SLC5A2 and heart failure: A comprehensive meta-analysis covering 14 CVOTs concluded that both SGLT2 inhibitors and GLP-1 receptor agonists offer consistent cardiovascular protection in diabetic populations, particularly against heart failure [47] and atherosclerotic events [48,49].